YCBD - cbdmd.com Debt to Book Capitalization Ratio

Graphic logo of cbdMD (YCBD)

The ratio of debt to book capitalization underscores the status of cbdMD, Inc. (YCBD) as a reputable supplier for athletes with high purification standards. This metric remains around 0.27, correlating with investments in R&D and extract purity verification. Current growth relies on online sales and retail while opportunities for global market expansion are being developed.

YCBD (cbdMD) Debt to Book Value history from 07/04/2022 to 10/27/2026
Core merchandise of cbdMD

Determining fundamental stability requires separating real solvency from short-term price fluctuations. This indicator measures the share of borrowed funds in total asset value to determine the level of financial leverage. Analyzing debt obligations relative to the balance sheet capital structure allows for an assessment of credit shock risk. For cbdMD, Inc. (YCBD), low leverage confirms stability during the implementation of eco-friendly packaging standards. Controlling the debt load guarantees the continued development of cannabidiol product manufacturing.

Competitors of cbdMD, Inc.

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio tonixpharma.com (TNXP)|China SXT Pharmaceuticals, Inc. - Debts to Book Capitalization|Debt to Book Value Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Debts to Book Capitalization|EXOZ - Debt to Book Capitalization Ratio|Debts to Book Capitalization oramed.com|ENTX (Entera Bio) - Debt to Book Value Ratio|Debt to Book Capitalization Ratio HYFT|Debt to Book Value ABVC BioPharma Inc.|Debts to Book Capitalization Cumberland Pharma CPIX|Debt to Book Value Ratio Quantum BioPharma Corp QNTM|Debt to Book Value FibroGen, Inc.|Debt to Net Assets Ratio telomirpharma.com TELO|Debts to Book Capitalization RANI (Rani Therapeutics Inc)|SNYR: Debts to Net Assets|Debt to Book Capitalization Ratio rallybio.com|Lexaria Bioscience Corp. (LEXX) - Debt to Book Value Ratio|Debts to Book Capitalization PULM|Debt to Book Value Pheton (PTHL)|APM (Aptorum Group Limited) - Debt to Book Value|Debts to Net Assets Lyra Therapeutics Inc. LYRA|IBO: Debt to Book Value|Debts to Book Value TNF Pharmaceuticals Inc. TNFA|PRFX: Debts to Book Capitalization|CYTO - Debt to Book Value|Lipella Pharmaceuticals, Inc. (LIPO) - Debts to Book Capitalization|OptiNose Inc (OPTN) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Pieris (PIRS)|Debt to Book Value Ratio PROC|PTPI - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio qlsyy.net (QLI)|Debts to Book Capitalization ACELYRIN|Debt to Net Assets Ratio TFF Pharmaceuticals Inc. TFFP